<html>
  <head>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on May 22, 2025</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
    </div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">National Healthcare Properties, Inc.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div style="text-align: center;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zd7b2b393ab084c6aad195df579ea96de" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Maryland</div>
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation or organization)</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1"><br>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">38-3888962</div>
            <div style="text-align: center; font-weight: bold;">(IRS Employer Identification Number)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="1" colspan="1"><br>
          </td>
          <td style="width: 49%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top; font-weight: bold; text-align: center;" rowspan="1">540 Madison Ave., 27th Floor, New York, NY</td>
          <td style="width: 2%; vertical-align: top; font-weight: bold; text-align: center;" rowspan="1" colspan="1"><br>
          </td>
          <td style="width: 49%; vertical-align: top; font-weight: bold; text-align: center;" rowspan="1">10022</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top; font-weight: bold; text-align: center;" rowspan="1">(Address of principal executive offices)</td>
          <td style="width: 2%; vertical-align: top; font-weight: bold; text-align: center;" rowspan="1" colspan="1"><br>
          </td>
          <td style="width: 49%; vertical-align: top; text-align: center;" rowspan="1">(Zip code)</td>
        </tr>

    </table>
    <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
    </div>
    <div style="text-align: center; font-weight: bold;">2025 Omnibus Incentive Compensation Plan of National Healthcare Properties, Inc.</div>
    <div style="text-align: center; font-weight: bold;">(Full title of the Plan)</div>
    <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Michael Anderson</div>
    <div style="text-align: center; font-weight: bold;">Chief Executive Officer and President</div>
    <div style="text-align: center; font-weight: bold;">National Healthcare Properties, Inc.</div>
    <div style="text-align: center; font-weight: bold;">540 Madison Ave, 27th Floor</div>
    <div style="text-align: center; font-weight: bold;">New York, NY 10022</div>
    <div style="text-align: center;">(Name and address of agent for service)</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">(332) 258-8770</div>
    <div style="text-align: center;">(Telephone number, including area code, of agent for service)</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Joseph A. Herz, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Win Rutherfurd, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Greenberg Traurig, LLP</div>
    <div style="text-align: center; font-weight: bold;">One Vanderbilt Avenue</div>
    <div style="text-align: center; font-weight: bold;">New York, New York 10017</div>
    <div style="text-align: center; font-weight: bold;">Tel: (212) 801-9200</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large
      accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7c670bbbdab54060a1e074ee37a65085" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 22%; vertical-align: top;">
            <div>Large accelerated filer</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: center;">&#9744;</div>
          </td>
          <td style="width: 42%; vertical-align: top;">&#160;</td>
          <td style="width: 19%; vertical-align: top;">
            <div style="text-align: center;">Accelerated filer</div>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div style="text-align: center;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22%; vertical-align: top;">
            <div>Non-accelerated filer</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: center;">&#9746;</div>
          </td>
          <td style="width: 42%; vertical-align: top;">&#160;</td>
          <td style="width: 19%; vertical-align: top;">
            <div style="text-align: center;">Smaller reporting company</div>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div style="text-align: center;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 42%; vertical-align: top;">&#160;</td>
          <td style="width: 19%; vertical-align: top;">
            <div style="text-align: center;">Emerging growth company</div>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div style="text-align: center;">&#9744;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section 7(a)(2)(B) of the Securities Act. &#9744;</div>
    <div>&#160;</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART I</div>
    <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
    <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
    </div>
    <div style="text-align: justify;">The documents containing the information specified in Part I of Form S-8 will be sent or given to the persons participating in the 2025 Omnibus Incentive Compensation Plan (the &#8220;Plan&#8221;) of National Healthcare
      Properties, Inc. (the &#8220;Company&#8221;), as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In accordance with the instructions to Part I of Form S-8, such documents need not be filed with the Securities and
      Exchange Commission (the &#8220;Commission&#8221;) either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents (or portions thereof as permitted by Rule
      428(b)) and the documents incorporated by reference in this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities
      Act.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7c1880b99f09407bac4c1e46d3c658f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Incorporation of Documents by Reference.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: justify;">The following documents, which the Company has previously filed with the Commission, are hereby incorporated by reference into this registration statement (excluding any information that is deemed to have been
      &#8220;furnished&#8221; and not &#8220;filed&#8221; with the Commission, including any Item 2.02 or Item 7.01 of any Current Report on Form 8-K):</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd7e2fe5ff3aa4e488bf532f297d698cd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company&#8217;s Annual Report on<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1561032/000156103225000006/hct-20241231.htm"> Form 10-K for the year ended December 31, 2024</a>, filed with the Commission on February 27, 2025;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zb2062e9ed02041c2ab1f4377a13f0933" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company&#8217;s Quarterly Report on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1561032/000156103225000016/hct-20250331.htm">Form 10-Q for the quarter ended March 31, 2025,</a> filed with the Commission on May 8, 2025;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z6c42eb17d7ac4f79872c766e94d595b8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1561032/000114036125013458/ny20043219x1_def14a.htm">Definitive Proxy Statement on Schedule 14A,</a> filed with the Commission on April 11, 2025 (solely to the extent
              incorporated by reference into Part III of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024);</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z08649a16b62345d19e042e8b291b357b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company&#8217;s Current Report on Form 8-K, filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1561032/000156103225000013/hct-20250326.htm">March 26, 2025</a>;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z7dc8def99212492291482beea0567f0a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The description of the Company&#8217;s common stock, par value $0.01 per share (&#8220;common stock&#8221;), included in the Company&#8217;s Registration Statement on <a href="https://www.sec.gov/Archives/edgar/data/1561032/000114420414026450/v376411_8a12g.htm">Form





                8-A,</a> filed with the Commission on April 30, 2014, including any amendment or report filed for the purpose of updating such description, including the description of the common stock filed as Exhibit 4.9 to the Company&#8217;s Annual Report on
              Form 10-K, filed with the Commission on February 27, 2025; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z12650136698a42c595f7879577d30775" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The description of common stock purchase rights included in the Company&#8217;s Registration Statement on <a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465920133253/tm2038016-1_8a12g.htm">Form 8-A</a> and <a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465923062334/tm2316166d1_8a12ga.htm">Form 8-A/A</a> filed with the Commission on December 8, 2020 and May 19, 2023, respectively.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;">In addition, all documents and reports subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (excluding any information that is deemed to
      have been &#8220;furnished&#8221; and not &#8220;filed&#8221; with the Commission, including any Items 2.02, 7.01 or 9.01 of any Current Report on Form 8-K), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or
      which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents or reports. Any statement contained in a document
      incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which
      also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration
      statement.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z078a3246430e431d8345abb716e9c0b9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Description of Securities.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: justify;">Not applicable.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zfac1ddb9a0d64f5194a3d6004f5961cd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Interests of Named Experts and Counsel.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: justify;">Not applicable.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb8ecd505e3604cc89ce8747ddb0ba066" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Indemnification of Directors and Officers.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: justify;">Maryland law permits a Maryland corporation to include in its charter a provision eliminating the liability of its directors and officers to the corporation and its stockholders for money damages except for liability
      resulting from (1) actual receipt of an improper benefit or profit in money, property or services or (2) active and deliberate dishonesty established by a final judgment as being material to the cause of action. The Company&#8217;s charter contains a
      provision that eliminates such liability to the maximum extent permitted by Maryland law. This provision does not reduce the exposure of directors and officers to liability under federal or state securities laws, nor does it limit the stockholders&#8217;
      ability to obtain injunctive relief or other equitable remedies for a violation of a director&#8217;s or an officer&#8217;s duties to the Company, although the equitable remedies may not be an effective remedy in some circumstances.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify;">The Maryland General Corporation Law (the &#8220;MGCL&#8221;) requires a Maryland corporation (unless its charter provides otherwise, which the Company&#8217;s charter does not) to indemnify a director or officer who has been
      successful, on the merits or otherwise, in the defense of any proceeding to which he or she is made or threatened to be made a party by reason of his or her service in that capacity. The MGCL permits a Maryland corporation to indemnify its present
      and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they may be made or threatened to be made a party by reason
      of their service in those or other capacities unless it is established that (1) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (A) was committed in bad faith or (B) was the result of active
      and deliberate dishonesty, (2) the director or officer actually received an improper personal benefit in money, property or services, or (3) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act
      or omission was unlawful. However, under the MGCL, a Maryland corporation may not indemnify a director or officer for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal
      benefit was improperly received. A court may order indemnification if it determines that the director or officer is fairly and reasonably entitled to indemnification, even though the director or officer did not meet the prescribed standard of conduct
      or was adjudged liable on the basis that personal benefit was improperly received. However, indemnification for an adverse judgment in a suit by its or in the Company&#8217;s right, or for a judgment of liability on the basis that personal benefit was
      improperly received, is limited to expenses.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify;">In addition, the MGCL permits a corporation to advance reasonable expenses to a director or officer upon the corporation&#8217;s receipt of (1) a written affirmation by the director or officer of his or her good faith belief
      that he or she has met the standard of conduct necessary for indemnification by the corporation and (2) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately
      determined that the appropriate standard of conduct was not met.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify;">The Company&#8217;s charter authorizes the Company to obligate itself and the Company&#8217;s bylaws obligate the Company, to the fullest extent permitted by Maryland law in effect from time to time, to indemnify and, without
      requiring a preliminary determination of the ultimate entitlement to indemnification, pay or reimburse reasonable expenses in advance of final disposition of a proceeding to:</div>
    <div> <br>
      <table cellspacing="0" cellpadding="0" id="z705d45b41f47423fb645757b869890db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>any present or former director or officer who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity; or</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zc29c80891efc49a5b705c9c2726a2d5b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>any individual who, while a director or officer of the Company and at the Company&#8217;s request, serves or has served as a director, officer, member, manager, partner or trustee of another corporation, real estate investment trust, limited
                liability company, joint venture, partnership, trust, employee benefit plan or other enterprise and who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: justify;">The Company&#8217;s charter and bylaws also permit the Company, with the approval of our Board of Directors, to indemnify and advance expenses to any person who served a predecessor of the Company in any of the capacities
        described above and to any employee or agent of the Company or a predecessor of the Company.</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div style="text-align: justify;">The Company has entered into an indemnification agreement with each of its directors and officers and certain former directors and officers, providing for indemnification of such directors and officers to the maximum
        extent permitted by Maryland law. The indemnification agreements provide that each indemnitee is entitled to indemnification unless it is established that (1) the act or omission of an indemnitee was material to the matter giving rise to the
        proceeding and (i) was committed in bad faith or (ii) was the result of active and deliberate dishonesty, (2) such indemnitee actually received an improper personal benefit in money, property or services or (3) in the case of any criminal
        proceeding, such indemnitee had reasonable cause to believe that his or her conduct was unlawful. The indemnification agreements further limit each indemnitee&#8217;s entitlement to indemnification in cases where (1) the proceeding was one by or in the
        right of the Company and such indemnitee was adjudged, to be liable to the Company, (2) such indemnitee was adjudged, to be liable on the basis that personal benefit was improperly received in any proceeding charging improper personal benefit to
        such indemnitee or (3) the proceeding was brought by such indemnitee, except in certain circumstances.</div>
      <div> <br>
      </div>
      <div style="text-align: justify;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, the Company has been
        informed that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z929ddf093ac2457fa6b8be91ab265ae5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 7.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exemption from Registration Claimed.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: justify;">Not applicable.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z627d8893f21d4b07ae63e528491130a2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 8.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exhibits.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: justify;">See attached Exhibit Index.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za5e8369f48ba4bdbbf937279d98a02fe" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">Item 9.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Undertakings.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3055e19a098c4122a84185fc41515243" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">(a)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The undersigned registrant hereby undertakes:</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3c16ef5e6dbe4eb5b494ea92f1381cac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">(1)</td>
            <td style="width: auto; vertical-align: top;">
              <div>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z350a59ebb5fe40359d6ebde5ea13d38b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">(i)</td>
            <td style="width: auto; vertical-align: top;">
              <div>to include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z4061148183a74f7984f2e89fc946fd29" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">(ii)</td>
            <td style="width: auto; vertical-align: top;">
              <div>to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
                in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
                and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
                no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z2fd9205fe3c34419acbd52bdd93a13ab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">(iii)</td>
            <td style="width: auto; vertical-align: top;">
              <div>to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: justify;">provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with
        or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z5566c7ab0d6b4de093b957dcc64374ff" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">(2)</td>
            <td style="width: auto; vertical-align: top;">
              <div>That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
                such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zfe06314896d44bbc9fcc250aa5a697ff" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">(3)</td>
            <td style="width: auto; vertical-align: top;">
              <div>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: justify;">(b)&#160; &#160; &#160; &#160; &#160;&#160; The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to section 13(a) or
        section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
        registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">(c)&#160; &#160; &#160; &#160; &#160;&#160; Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
        provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a
        claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
        asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
        appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="text-align: center;"><font style="font-weight: bold;"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="za6276b6826b6468895d1567f943d379b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 11%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Exhibit No</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000162828024047225/ex31.htm">4.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Composite Articles of Amendment and Restatement for the Company (filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Commission on November 12, 2024 and incorporated
                by reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000156103217000011/ex31articlessupplementary.htm">4.2</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div>Articles Supplementary of the Company relating to election to be subject to Section 3-803 of the Maryland General Corporation Law, dated November 9, 2017 (filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter
                ended September 30, 2017 filed with the Commission on November 14, 2017 and incorporated by reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465924104019/tm2425086d1_ex3-1.htm">4.3</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Articles of Amendment to the Company&#8217;s Charter, filed September 26, 2024 (Reverse Stock Split) (filed as an exhibit to the Company&#8217;s Current Report on Form 8-K filed with the Commission on September 30, 2024 and incorporated by reference
                herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465924104019/tm2425086d1_ex3-2.htm">4.4</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div>Articles of Amendment to the Company&#8217;s Charter, filed September 26, 2024 (Name Change and Par Value Adjustment) (filed as an exhibit to the Company&#8217;s Current Report on Form 8-K filed with the Commission on September 30, 2024 and
                incorporated by reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000162828024047225/ex32.htm">4.5</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Composite Amended and Restated Bylaws of the Company (filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Commission on November 12, 2024 and incorporated by
                reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465924104019/tm2425086d1_ex3-3.htm">4.6</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div>Amendment No. 3 to the Amended and Restated Bylaws of the Company (filed as an exhibit to the Company&#8217;s Current Report on Form 8-K filed with the Commission on September 30, 2024 and incorporated by reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465920063345/tm2020139d1_ex4-1.htm">4.7</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Rights Agreement, dated May 18, 2020, between the Company and Computershare Trust Company, N.A., as Rights Agent (filed as an exhibit to the Company&#8217;s Current Report on Form 8-K filed with the Commission on May 19, 2020 and incorporated
                by reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1561032/000110465923062334/tm2316166d1_ex4-2.htm">4.8</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div>Amendment No. 1, dated May 18, 2023, to the Rights Agreement, dated May 18, 2020, between the Company and Computershare Trust Company, N.A., as Rights Agent (filed as an exhibit to the Company&#8217;s Registration Statement on Form 8-A/A filed
                with the Commission on May 19, 2023 and incorporated by reference herein)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="ef20049538_ex5-1.htm">5.1 *</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Opinion of Venable LLP regarding legality of securities being registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div style="text-align: justify;"><a href="ef20049538_ex5-1.htm">23.1 *</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: justify;">Consent of Venable LLP (included in Exhibit 5.1)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="ef20049538_ex23-2.htm">23.2 *</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Consent of PricewaterhouseCoopers LLP</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div style="text-align: justify;"><a href="#POWEROFATTORNEY">24.1 *</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: justify;">Power of Attorney (included on signature page hereto)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="ef20049538_ex99-1.htm">99.1*</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">2025 Omnibus Incentive Compensation Plan of National Healthcare Properties, Inc., effective as of May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11%; vertical-align: top;">
              <div style="text-align: justify;"><a href="ef20049538_ex107.htm">107 *</a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 87%; vertical-align: top;">
              <div style="text-align: justify;">Filing Fee Table</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z7a6b98d25ee141c2a1849cefd41baf9a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 2%; vertical-align: top;">
              <div>*</div>
            </td>
            <td style="width: 98%; vertical-align: top;">
              <div style="text-align: justify;">Filed herewith</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div> <br>
      </div>
      <div style="text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
        caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on May 22, 2025.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zcf2eb9e6d9ce42338131d2fa97be9b98" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;" colspan="2">
              <div>National Healthcare Properties, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 50%; vertical-align: bottom;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 5%; vertical-align: bottom;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Michael Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 5%; vertical-align: bottom;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: bottom;">
              <div>&#160;Michael Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">&#160;</td>
            <td style="width: 5%; vertical-align: bottom;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: bottom;">
              <div>Chief Executive Officer and President</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="ss1"></a><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
      <div style="text-align: center;"> <br>
      </div>
      <div style="text-align: justify;">Each person whose signature appears below hereby constitutes and appoints Michael Anderson and Scott Lappetito<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>as her or his attorneys-in-fact and agent, with full power of substitution and resubstitution,
        for her or him in any and all capacities, in connection with this Registration Statement on Form S-8 (the &#8220;Registration Statement&#8221;) of National Healthcare Properties, Inc., under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)
        relating to the 2025 Omnibus Incentive Compensation Plan of National Healthcare Properties, Inc., including, without limiting the generality of the foregoing, to sign any amendments and supplements relating to the Registration Statement (including
        post-effective amendments) under the Securities Act and to sign any instrument, contract, document or other writing of or in connection with any amendments and supplements relating to the Registration Statement (including post-effective amendments)
        and to file the same, with all exhibits thereto, and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body,
        granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he
        might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb92f6bab31cf4a4e9597d5f36fedd675" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Signatures</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Title</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;" rowspan="1"><br>
            </td>
            <td style="width: 2%; vertical-align: middle;" rowspan="1"><br>
            </td>
            <td style="width: 32%; vertical-align: middle;" rowspan="1"><br>
            </td>
            <td style="width: 2%; vertical-align: middle;" rowspan="1"><br>
            </td>
            <td style="width: 32%; vertical-align: top;" rowspan="1"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">/s/ Michael Anderson</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Director, Chief Executive Officer and President (Principal Executive Officer)</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">Michael Anderson</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Scott. M. Lappetito</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">Scott. M. Lappetito</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Leslie D. Michelson</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Non-Executive Chair</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">Leslie D. Michelson</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Elizabeth K. Tuppeny</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Independent Director</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">Elizabeth K. Tuppeny</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ B.J. Penn</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Independent Director</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">B.J. Penn</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Edward G. Rendell</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Independent Director</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">Edward G. Rendell</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Edward M. Weil, Jr.</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: middle;" rowspan="2">
              <div>Director</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">May 22, 2025</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center;">Edward M. Weil, Jr.</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div> <br>
      </div>
      <br>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <!-- base href="file:///C:/Users/JadupulaH/AppData/Local/Temp/PROfile%20Green/32srj53w.vbt/expand/content/ef20049538_s8.htm" -->
  <title></title>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ef20049538_s8.htm", "description": "S-8", "secsgml_size_bytes": 67014}]
{"company-data": {"conformed-name": "National Healthcare Properties, Inc.", "cik": "0001561032", "assigned-sic": "6798", "organization-name": "05 Real Estate & Construction", "ein": "383888962", "state-of-incorporation": "MD", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-287527", "film-number": "25978204"}, "business-address": {"street1": "540 MADISON AVE, 27TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022", "phone": "212-415-6500"}, "mail-address": {"street1": "540 MADISON AVE, 27TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022"}, "former-company": [{"former-conformed-name": "Healthcare Trust, Inc.", "date-changed": "20150811"}, {"former-conformed-name": "American Realty Capital Healthcare Trust II, Inc.", "date-changed": "20121025"}]}
As filed with the Securities and Exchange Commission on May 22, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
National Healthcare Properties, Inc.
(Exact name of registrant as specified in its charter)
Maryland
(State or other jurisdiction of incorporation or organization)
38-3888962
(IRS Employer Identification Number)
540 Madison Ave., 27th Floor, New York, NY
10022
(Address of principal executive offices)
(Zip code)
2025 Omnibus Incentive Compensation Plan of National Healthcare Properties, Inc.
(Full title of the Plan)
Michael Anderson
Chief Executive Officer and President
National Healthcare Properties, Inc.
540 Madison Ave, 27th Floor
New York, NY 10022
(Name and address of agent for service)
(332) 258-8770
(Telephone number, including area code, of agent for service)
Copies to:
Joseph A. Herz, Esq.
Win Rutherfurd, Esq.
Greenberg Traurig, LLP
One Vanderbilt Avenue
New York, New York 10017
Tel: (212) 801-9200
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large
      accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I of Form S-8 will be sent or given to the persons participating in the 2025 Omnibus Incentive Compensation Plan (the "Plan") of National Healthcare
      Properties, Inc. (the "Company"), as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"). In accordance with the instructions to Part I of Form S-8, such documents need not be filed with the Securities and
      Exchange Commission (the "Commission") either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents (or portions thereof as permitted by Rule
      428(b)) and the documents incorporated by reference in this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities
      Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The following documents, which the Company has previously filed with the Commission, are hereby incorporated by reference into this registration statement (excluding any information that is deemed to have been
      "furnished" and not "filed" with the Commission, including any Item 2.02 or Item 7.01 of any Current Report on Form 8-K):
•
The Company's Annual Report on
Form 10-K for the year ended December 31, 2024
, filed with the Commission on February 27, 2025;
•
The Company's Quarterly Report on
Form 10-Q for the quarter ended March 31, 2025,
filed with the Commission on May 8, 2025;
•
The Company's
Definitive Proxy Statement on Schedule 14A,
filed with the Commission on April 11, 2025 (solely to the extent
              incorporated by reference into Part III of the Company's Annual Report on Form 10-K for the year ended December 31, 2024);
•
The Company's Current Report on Form 8-K, filed with the Commission on
March 26, 2025
;
•
The description of the Company's common stock, par value $0.01 per share ("common stock"), included in the Company's Registration Statement on
Form

                8-A,
filed with the Commission on April 30, 2014, including any amendment or report filed for the purpose of updating such description, including the description of the common stock filed as Exhibit 4.9 to the Company's Annual Report on
              Form 10-K, filed with the Commission on February 27, 2025; and
•
The description of common stock purchase rights included in the Company's Registration Statement on
Form 8-A
and
Form 8-A/A
filed with the Commission on December 8, 2020 and May 19, 2023, respectively.
In addition, all documents and reports subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (excluding any information that is deemed to
      have been "furnished" and not "filed" with the Commission, including any Items 2.02, 7.01 or 9.01 of any Current Report on Form 8-K), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or
      which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents or reports. Any statement contained in a document
      incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which
      also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration
      statement.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
Not applicable.
Item 6.
Indemnification of Directors and Officers.
Maryland law permits a Maryland corporation to include in its charter a provision eliminating the liability of its directors and officers to the corporation and its stockholders for money damages except for liability
      resulting from (1) actual receipt of an improper benefit or profit in money, property or services or (2) active and deliberate dishonesty established by a final judgment as being material to the cause of action. The Company's charter contains a
      provision that eliminates such liability to the maximum extent permitted by Maryland law. This provision does not reduce the exposure of directors and officers to liability under federal or state securities laws, nor does it limit the stockholders'
      ability to obtain injunctive relief or other equitable remedies for a violation of a director's or an officer's duties to the Company, although the equitable remedies may not be an effective remedy in some circumstances.
The Maryland General Corporation Law (the "MGCL") requires a Maryland corporation (unless its charter provides otherwise, which the Company's charter does not) to indemnify a director or officer who has been
      successful, on the merits or otherwise, in the defense of any proceeding to which he or she is made or threatened to be made a party by reason of his or her service in that capacity. The MGCL permits a Maryland corporation to indemnify its present
      and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they may be made or threatened to be made a party by reason
      of their service in those or other capacities unless it is established that (1) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (A) was committed in bad faith or (B) was the result of active
      and deliberate dishonesty, (2) the director or officer actually received an improper personal benefit in money, property or services, or (3) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act
      or omission was unlawful. However, under the MGCL, a Maryland corporation may not indemnify a director or officer for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal
      benefit was improperly received. A court may order indemnification if it determines that the director or officer is fairly and reasonably entitled to indemnification, even though the director or officer did not meet the prescribed standard of conduct
      or was adjudged liable on the basis that personal benefit was improperly received. However, indemnification for an adverse judgment in a suit by its or in the Company's right, or for a judgment of liability on the basis that personal benefit was
      improperly received, is limited to expenses.
In addition, the MGCL permits a corporation to advance reasonable expenses to a director or officer upon the corporation's receipt of (1) a written affirmation by the director or officer of his or her good faith belief
      that he or she has met the standard of conduct necessary for indemnification by the corporation and (2) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately
      determined that the appropriate standard of conduct was not met.
The Company's charter authorizes the Company to obligate itself and the Company's bylaws obligate the Company, to the fullest extent permitted by Maryland law in effect from time to time, to indemnify and, without
      requiring a preliminary determination of the ultimate entitlement to indemnification, pay or reimburse reasonable expenses in advance of final disposition of a proceeding to:
•
any present or former director or officer who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity; or
•
any individual who, while a director or officer of the Company and at the Company's request, serves or has served as a director, officer, member, manager, partner or trustee of another corporation, real estate investment trust, limited
                liability company, joint venture, partnership, trust, employee benefit plan or other enterprise and who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity.
The Company's charter and bylaws also permit the Company, with the approval of our Board of Directors, to indemnify and advance expenses to any person who served a predecessor of the Company in any of the capacities
        described above and to any employee or agent of the Company or a predecessor of the Company.
The Company has entered into an indemnification agreement with each of its directors and officers and certain former directors and officers, providing for indemnification of such directors and officers to the maximum
        extent permitted by Maryland law. The indemnification agreements provide that each indemnitee is entitled to indemnification unless it is established that (1) the act or omission of an indemnitee was material to the matter giving rise to the
        proceeding and (i) was committed in bad faith or (ii) was the result of active and deliberate dishonesty, (2) such indemnitee actually received an improper personal benefit in money, property or services or (3) in the case of any criminal
        proceeding, such indemnitee had reasonable cause to believe that his or her conduct was unlawful. The indemnification agreements further limit each indemnitee's entitlement to indemnification in cases where (1) the proceeding was one by or in the
        right of the Company and such indemnitee was adjudged, to be liable to the Company, (2) such indemnitee was adjudged, to be liable on the basis that personal benefit was improperly received in any proceeding charging improper personal benefit to
        such indemnitee or (3) the proceeding was brought by such indemnitee, except in certain circumstances.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, the Company has been
        informed that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
See attached Exhibit Index.
Item 9.
Undertakings.
(a)
The undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
to include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
(ii)
to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
                in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
                and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
                no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with
        or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
                such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b)           The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or
        section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
        registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)           Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
        provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a
        claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
        asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
        appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
EXHIBIT INDEX
Exhibit No
Description
4.1
Composite Articles of Amendment and Restatement for the Company (filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Commission on November 12, 2024 and incorporated
                by reference herein)
4.2
Articles Supplementary of the Company relating to election to be subject to Section 3-803 of the Maryland General Corporation Law, dated November 9, 2017 (filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter
                ended September 30, 2017 filed with the Commission on November 14, 2017 and incorporated by reference herein)
4.3
Articles of Amendment to the Company's Charter, filed September 26, 2024 (Reverse Stock Split) (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on September 30, 2024 and incorporated by reference
                herein)
4.4
Articles of Amendment to the Company's Charter, filed September 26, 2024 (Name Change and Par Value Adjustment) (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on September 30, 2024 and
                incorporated by reference herein)
4.5
Composite Amended and Restated Bylaws of the Company (filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Commission on November 12, 2024 and incorporated by
                reference herein)
4.6
Amendment No. 3 to the Amended and Restated Bylaws of the Company (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on September 30, 2024 and incorporated by reference herein)
4.7
Rights Agreement, dated May 18, 2020, between the Company and Computershare Trust Company, N.A., as Rights Agent (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Commission on May 19, 2020 and incorporated
                by reference herein)
4.8
Amendment No. 1, dated May 18, 2023, to the Rights Agreement, dated May 18, 2020, between the Company and Computershare Trust Company, N.A., as Rights Agent (filed as an exhibit to the Company's Registration Statement on Form 8-A/A filed
                with the Commission on May 19, 2023 and incorporated by reference herein)
5.1 *
Opinion of Venable LLP regarding legality of securities being registered
23.1 *
Consent of Venable LLP (included in Exhibit 5.1)
23.2 *
Consent of PricewaterhouseCoopers LLP
24.1 *
Power of Attorney (included on signature page hereto)
99.1*
2025 Omnibus Incentive Compensation Plan of National Healthcare Properties, Inc., effective as of May 22, 2025
107 *
Filing Fee Table
*
Filed herewith
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
        caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on May 22, 2025.
National Healthcare Properties, Inc.
By:
/s/ Michael Anderson
Name:
Michael Anderson
Title:
Chief Executive Officer and President
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Michael Anderson and Scott Lappetito
as her or his attorneys-in-fact and agent, with full power of substitution and resubstitution,
        for her or him in any and all capacities, in connection with this Registration Statement on Form S-8 (the "Registration Statement") of National Healthcare Properties, Inc., under the Securities Act of 1933, as amended (the "Securities Act")
        relating to the 2025 Omnibus Incentive Compensation Plan of National Healthcare Properties, Inc., including, without limiting the generality of the foregoing, to sign any amendments and supplements relating to the Registration Statement (including
        post-effective amendments) under the Securities Act and to sign any instrument, contract, document or other writing of or in connection with any amendments and supplements relating to the Registration Statement (including post-effective amendments)
        and to file the same, with all exhibits thereto, and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body,
        granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he
        might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signatures
Title
Date
/s/ Michael Anderson
Director, Chief Executive Officer and President (Principal Executive Officer)
May 22, 2025
Michael Anderson
/s/ Scott. M. Lappetito
Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)
May 22, 2025
Scott. M. Lappetito
/s/ Leslie D. Michelson
Non-Executive Chair
May 22, 2025
Leslie D. Michelson
/s/ Elizabeth K. Tuppeny
Independent Director
May 22, 2025
Elizabeth K. Tuppeny
/s/ B.J. Penn
Independent Director
May 22, 2025
B.J. Penn
/s/ Edward G. Rendell
Independent Director
May 22, 2025
Edward G. Rendell
/s/ Edward M. Weil, Jr.
Director
May 22, 2025
Edward M. Weil, Jr.